Treatment and clinical management of primary mediastinal large B-cell lymphoma with sclerosis: MACOP-B regimen and mediastinal radiotherapy monitored by 67Gallium scan in 50 patients

Pier Luigi Zinzani, Maurizio Martelli, Massimo Magagnoli, Edoardo Pescarmona, Laura Scaramucci, Francesca Palombi, Maurizio Bendandi, Maria Paola Martelli, Stefano Ascani, Giulio Fraternali Orcioni, Stefano A. Pileri, Franco Mandelli, Sante Tura

Research output: Contribution to journalArticle

104 Citations (Scopus)

Abstract

To evaluate the efficacy of a combined modality treatment (MACOP-B plus mediastinal radiotherapy) and the advantages of Gallium-67-citrate single- photon emission (67Ga-SPECT) over computed tomography (CT) for restaging in patients with primary mediastinal large B-cell lymphoma (PMLBCL) with sclerosis. Between 1989 and 1998, 50 previously untreated patients with PMLBCL with sclerosis (70% with bulky mass) were treated with MACOP-B regimen plus mediastinal radiotherapy. The radiologic clinical stage with evaluation of tumor size included CT and 67GaSPECT at diagnosis, after chemotherapy, and after radiotherapy. Forty-three patients (86%) achieved a complete response and 7 were nonresponders to treatment. For the imaging evaluation, only 47 patients were evaluable because 3 had disease progression during chemotherapy. After treatment, 3/5 (60%) patients with positive 67GaSPECT and negative CT scan relapsed, as against 0/21 (0%) with negative 67GaSPECT and CT scan. Twenty-one patients had a positive CT scan: of these, the 4 with positive 67GaSPECT all progressed, whereas there were no relapses among the 17 with negative 67GaSPECT. After radiotherapy, there was a decrease of positive CT (from 33 to 21 cases) and of positive 67GaSPECT (from 31 to 9 cases). Relapse-free survival rate was 93% at 96 months (median 39 months). In patients with PMLBCL with sclerosis, MACOP-B plus radiation therapy is a very useful first-line treatment and radiation therapy may play an important role. As regards restaging, 67GaSPECT should be considered the imaging technique of choice at least in patients who show CT positivity.

Original languageEnglish
Pages (from-to)3289-3293
Number of pages5
JournalBlood
Volume94
Issue number10
Publication statusPublished - Nov 15 1999

Fingerprint

Radiotherapy
Sclerosis
B-Cell Lymphoma
Tomography
Cells
Chemotherapy
Therapeutics
Imaging techniques
Recurrence
Drug Therapy
MACOP-B regimen
Single-Photon Emission-Computed Tomography
Photons
Tumors
Disease Progression
Survival Rate

ASJC Scopus subject areas

  • Hematology

Cite this

Zinzani, P. L., Martelli, M., Magagnoli, M., Pescarmona, E., Scaramucci, L., Palombi, F., ... Tura, S. (1999). Treatment and clinical management of primary mediastinal large B-cell lymphoma with sclerosis: MACOP-B regimen and mediastinal radiotherapy monitored by 67Gallium scan in 50 patients. Blood, 94(10), 3289-3293.

Treatment and clinical management of primary mediastinal large B-cell lymphoma with sclerosis : MACOP-B regimen and mediastinal radiotherapy monitored by 67Gallium scan in 50 patients. / Zinzani, Pier Luigi; Martelli, Maurizio; Magagnoli, Massimo; Pescarmona, Edoardo; Scaramucci, Laura; Palombi, Francesca; Bendandi, Maurizio; Martelli, Maria Paola; Ascani, Stefano; Orcioni, Giulio Fraternali; Pileri, Stefano A.; Mandelli, Franco; Tura, Sante.

In: Blood, Vol. 94, No. 10, 15.11.1999, p. 3289-3293.

Research output: Contribution to journalArticle

Zinzani, PL, Martelli, M, Magagnoli, M, Pescarmona, E, Scaramucci, L, Palombi, F, Bendandi, M, Martelli, MP, Ascani, S, Orcioni, GF, Pileri, SA, Mandelli, F & Tura, S 1999, 'Treatment and clinical management of primary mediastinal large B-cell lymphoma with sclerosis: MACOP-B regimen and mediastinal radiotherapy monitored by 67Gallium scan in 50 patients', Blood, vol. 94, no. 10, pp. 3289-3293.
Zinzani, Pier Luigi ; Martelli, Maurizio ; Magagnoli, Massimo ; Pescarmona, Edoardo ; Scaramucci, Laura ; Palombi, Francesca ; Bendandi, Maurizio ; Martelli, Maria Paola ; Ascani, Stefano ; Orcioni, Giulio Fraternali ; Pileri, Stefano A. ; Mandelli, Franco ; Tura, Sante. / Treatment and clinical management of primary mediastinal large B-cell lymphoma with sclerosis : MACOP-B regimen and mediastinal radiotherapy monitored by 67Gallium scan in 50 patients. In: Blood. 1999 ; Vol. 94, No. 10. pp. 3289-3293.
@article{419c91a37f6e4c19bd7f0481ba1291a2,
title = "Treatment and clinical management of primary mediastinal large B-cell lymphoma with sclerosis: MACOP-B regimen and mediastinal radiotherapy monitored by 67Gallium scan in 50 patients",
abstract = "To evaluate the efficacy of a combined modality treatment (MACOP-B plus mediastinal radiotherapy) and the advantages of Gallium-67-citrate single- photon emission (67Ga-SPECT) over computed tomography (CT) for restaging in patients with primary mediastinal large B-cell lymphoma (PMLBCL) with sclerosis. Between 1989 and 1998, 50 previously untreated patients with PMLBCL with sclerosis (70{\%} with bulky mass) were treated with MACOP-B regimen plus mediastinal radiotherapy. The radiologic clinical stage with evaluation of tumor size included CT and 67GaSPECT at diagnosis, after chemotherapy, and after radiotherapy. Forty-three patients (86{\%}) achieved a complete response and 7 were nonresponders to treatment. For the imaging evaluation, only 47 patients were evaluable because 3 had disease progression during chemotherapy. After treatment, 3/5 (60{\%}) patients with positive 67GaSPECT and negative CT scan relapsed, as against 0/21 (0{\%}) with negative 67GaSPECT and CT scan. Twenty-one patients had a positive CT scan: of these, the 4 with positive 67GaSPECT all progressed, whereas there were no relapses among the 17 with negative 67GaSPECT. After radiotherapy, there was a decrease of positive CT (from 33 to 21 cases) and of positive 67GaSPECT (from 31 to 9 cases). Relapse-free survival rate was 93{\%} at 96 months (median 39 months). In patients with PMLBCL with sclerosis, MACOP-B plus radiation therapy is a very useful first-line treatment and radiation therapy may play an important role. As regards restaging, 67GaSPECT should be considered the imaging technique of choice at least in patients who show CT positivity.",
author = "Zinzani, {Pier Luigi} and Maurizio Martelli and Massimo Magagnoli and Edoardo Pescarmona and Laura Scaramucci and Francesca Palombi and Maurizio Bendandi and Martelli, {Maria Paola} and Stefano Ascani and Orcioni, {Giulio Fraternali} and Pileri, {Stefano A.} and Franco Mandelli and Sante Tura",
year = "1999",
month = "11",
day = "15",
language = "English",
volume = "94",
pages = "3289--3293",
journal = "Blood",
issn = "0006-4971",
publisher = "American Society of Hematology",
number = "10",

}

TY - JOUR

T1 - Treatment and clinical management of primary mediastinal large B-cell lymphoma with sclerosis

T2 - MACOP-B regimen and mediastinal radiotherapy monitored by 67Gallium scan in 50 patients

AU - Zinzani, Pier Luigi

AU - Martelli, Maurizio

AU - Magagnoli, Massimo

AU - Pescarmona, Edoardo

AU - Scaramucci, Laura

AU - Palombi, Francesca

AU - Bendandi, Maurizio

AU - Martelli, Maria Paola

AU - Ascani, Stefano

AU - Orcioni, Giulio Fraternali

AU - Pileri, Stefano A.

AU - Mandelli, Franco

AU - Tura, Sante

PY - 1999/11/15

Y1 - 1999/11/15

N2 - To evaluate the efficacy of a combined modality treatment (MACOP-B plus mediastinal radiotherapy) and the advantages of Gallium-67-citrate single- photon emission (67Ga-SPECT) over computed tomography (CT) for restaging in patients with primary mediastinal large B-cell lymphoma (PMLBCL) with sclerosis. Between 1989 and 1998, 50 previously untreated patients with PMLBCL with sclerosis (70% with bulky mass) were treated with MACOP-B regimen plus mediastinal radiotherapy. The radiologic clinical stage with evaluation of tumor size included CT and 67GaSPECT at diagnosis, after chemotherapy, and after radiotherapy. Forty-three patients (86%) achieved a complete response and 7 were nonresponders to treatment. For the imaging evaluation, only 47 patients were evaluable because 3 had disease progression during chemotherapy. After treatment, 3/5 (60%) patients with positive 67GaSPECT and negative CT scan relapsed, as against 0/21 (0%) with negative 67GaSPECT and CT scan. Twenty-one patients had a positive CT scan: of these, the 4 with positive 67GaSPECT all progressed, whereas there were no relapses among the 17 with negative 67GaSPECT. After radiotherapy, there was a decrease of positive CT (from 33 to 21 cases) and of positive 67GaSPECT (from 31 to 9 cases). Relapse-free survival rate was 93% at 96 months (median 39 months). In patients with PMLBCL with sclerosis, MACOP-B plus radiation therapy is a very useful first-line treatment and radiation therapy may play an important role. As regards restaging, 67GaSPECT should be considered the imaging technique of choice at least in patients who show CT positivity.

AB - To evaluate the efficacy of a combined modality treatment (MACOP-B plus mediastinal radiotherapy) and the advantages of Gallium-67-citrate single- photon emission (67Ga-SPECT) over computed tomography (CT) for restaging in patients with primary mediastinal large B-cell lymphoma (PMLBCL) with sclerosis. Between 1989 and 1998, 50 previously untreated patients with PMLBCL with sclerosis (70% with bulky mass) were treated with MACOP-B regimen plus mediastinal radiotherapy. The radiologic clinical stage with evaluation of tumor size included CT and 67GaSPECT at diagnosis, after chemotherapy, and after radiotherapy. Forty-three patients (86%) achieved a complete response and 7 were nonresponders to treatment. For the imaging evaluation, only 47 patients were evaluable because 3 had disease progression during chemotherapy. After treatment, 3/5 (60%) patients with positive 67GaSPECT and negative CT scan relapsed, as against 0/21 (0%) with negative 67GaSPECT and CT scan. Twenty-one patients had a positive CT scan: of these, the 4 with positive 67GaSPECT all progressed, whereas there were no relapses among the 17 with negative 67GaSPECT. After radiotherapy, there was a decrease of positive CT (from 33 to 21 cases) and of positive 67GaSPECT (from 31 to 9 cases). Relapse-free survival rate was 93% at 96 months (median 39 months). In patients with PMLBCL with sclerosis, MACOP-B plus radiation therapy is a very useful first-line treatment and radiation therapy may play an important role. As regards restaging, 67GaSPECT should be considered the imaging technique of choice at least in patients who show CT positivity.

UR - http://www.scopus.com/inward/record.url?scp=0033571348&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0033571348&partnerID=8YFLogxK

M3 - Article

C2 - 10552937

AN - SCOPUS:0033571348

VL - 94

SP - 3289

EP - 3293

JO - Blood

JF - Blood

SN - 0006-4971

IS - 10

ER -